USP <788> Particulate Matter in Injections
Summary
USP General Chapter <788> is the primary, enforceable standard for controlling subvisible particulate matter in injectable drug products in the United States. Subvisible particles cannot be seen with the naked eye and include particles in the general scientific range of ~1–100 µm. USP <788> specifically regulates the ≥10 µm and ≥25 µm size thresholds. These particles are associated with safety risks including vascular blockage, inflammatory responses, and—particularly for protein therapeutics—heightened immunogenicity concerns.
Harmonization Status: <788> is harmonized under the Pharmacopoeial Discussion Group (PDG) with Ph. Eur. 2.9.19 and JP 6.07. Harmonization means the procedures and limits are considered interchangeable across the major compendia when applied according to each text.
Key Principles & Scope
Scope: The test applies to
- Small-Volume Injections (SVIs) with a volume of 100 mL or less, and
- Large-Volume Injections (LVIs) with a volume greater than 100 mL.
Test Methods:
Method 1: Light Obscuration Particle Count Test (LO)
- Principle: The sample is passed through a sensor. Particles block a light beam (laser diode), casting a shadow on a detector. The size of the shadow correlates to the particle size.
- Status: Preferred Method. It is fast, automated, and objective.
- Limitations: Not suitable for emulsions, liposomal dispersions, viscous formulations, products that create bubbles, or opaque/colored solutions.
Method 2: Microscopic Particle Count Test (Microscopy)
- Principle: The sample is filtered through a membrane filter (gridded, contrasting color). The filter is dried and examined under a microscope at 100x magnification.
- Status: Alternative & Referee Method. Used when Method 1 is technically impossible (e.g., for emulsions).
- The "Referee" Rule: When LO is not applicable or when LO results are questionable, microscopy may be used as the definitive method.
Acceptance Criteria (Harmonized Limits) Note that the limits for Method 2 are stricter (approximately half) than Method 1 because the microscope allows the analyst to distinguish "real" particles from artifacts.
Small-Volume Injections (SVI) (≤ 100 mL Nominal Volume)
-
Method 1 (LO):
-
≥ 10 µm: NMT 6000 per container
-
≥ 25 µm: NMT 600 per container
-
-
Method 2 (Microscopy):
-
≥ 10 µm: NMT 3000 per container
-
≥ 25 µm: NMT 300 per container
-
Large-Volume Injections (LVI) (> 100 mL Nominal Volume)
-
Method 1 (LO):
-
≥ 10 µm: NMT 25 per mL
-
≥ 25 µm: NMT 3 per mL
-
-
Method 2 (Microscopy):
-
≥ 10 µm: NMT 12 per mL
-
≥ 25 µm: NMT 2 per mL
-
Official Source
https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisionGeneralChapter788.pdf
Supporting Materials
- USP <1787> and <1788>
- USP<790> Visible Particulates in Injections
- USP<1> Injections and Implanted Drug Products (Parenterals)—Product Quality Tests
These related links show posts on this site that reference this page. They do not necessarily mean that this guidance directly applies to every modality, product type, or quality attribute listed below.
